Mucosal IgA responses in influenza virus infections; thoughts for vaccine design (Q38029860)

27 August 2017

Mucosal IgA responses in influenza virus infections; thoughts for vaccine design (English)

1 reference

27 August 2017

1 reference

1 reference

4

Hideki Hasegawa

1 reference

27 August 2017

Elly van Riet

1

1 reference

27 August 2017

Akira Ainai

series ordinal

2

1 reference

27 August 2017

Tadaki Suzuki

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

24 July 2012

1 reference

27 August 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

27 August 2017

30

1 reference

27 August 2017

40

1 reference

27 August 2017

5893-5900

1 reference

A question of self-preservation: immunopathology in influenza virus infection.

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Tissue-based class control: the other side of tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Induction of secretory immunity and memory at mucosal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Immune exclusion is a function of IgA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

7 January 2021

Selective IgA deficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Induction of heterosubtypic immunity to influenza virus by intranasal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Immunity to seasonal and pandemic influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Hallmarks of CD4 T cell immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

The regulation of IgA class switching.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

AID: how does it aid antibody diversity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Innate signals in mucosal immunoglobulin class switching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Vaccination strategies to promote mucosal antibody responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

B-cell fate decisions following influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Extrafollicular antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Intestinal bacteria condition dendritic cells to promote IgA production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Microbiota regulates immune defense against respiratory tract influenza A virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Inflammasomes as mediators of immunity against influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

N-linked glycosylation facilitates sialic acid-independent attachment and entry of influenza A viruses into cells expressing DC-SIGN or L-SIGN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Toll-like receptors--sentries in the B-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Identification of a novel antigen-presenting cell population modulating antiinfluenza type 2 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Follicular helper T cells as cognate regulators of B cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

TGF-beta receptor signaling is critical for mucosal IgA responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Immunity and immunological memory following smallpox vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

B-cell memory: are subsets necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Lymphoid reservoirs of antigen-specific memory T helper cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Influence of prior influenza vaccination on antibody and B-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Seasonal influenza vaccine and increased risk of pandemic A/H1N1‐related illness: first detection of the association in British Columbia, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Pandemic (H1N1) 2009 risk for nurses after trivalent vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Effector and regulatory B cells: modulators of CD4+ T cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Immunity to influenza in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Influenza at Christ's Hospital: March, 1974.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Recognition of single-stranded RNA viruses by Toll-like receptor 7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.109

10.1016/J.VACCINE.2012.04.109

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference